Blood cancer trial astounds again

A Phase 1b trial of a CAR T combination treatment for people who have failed multiple lines of therapy for a blood cancer is set to be expanded to more niche indications after an additional two patients achieved a complete response (CR) rate.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here